NCT02327936View on ClinicalTrials.gov

Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children

PHASE3CompletedINTERVENTIONAL

Enrollment

62

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

March 31, 2018

Study Completion Date

August 31, 2018

Conditions

Overactive Bladder

Interventions

DRUG

Fesoterodine

Administer medication to patients with overactive bladder

DRUG

Oxybutynin XL

Administer medication to patients with overactive bladder

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Pfizer

INDUSTRY

lead

Stéphane Bolduc

OTHER

NCT02327936 - Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children | Biotech Hunter | Biotech Hunter